PTO/SB/97 (08-00)
Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

On December 26, 2002

Date

Deborah A. Gunkel

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

The following forms are being transmitted herewith:

Transmittal Letter, one page (in duplicate);

Combined Notice of Appeal from the Primary Examiner

to the Board of Patent Appeals and Interferences

& Petition for Extension of Time Under 36 CFR 1.136(a)

two pages (in duplicate);

Power of Attorney by Assignee of Entire Interest

(Revocation of Prior Powers), with Statement under

37 CFR 3.373(b), four pages;

Amendment and Response to Office Action, ten pages.

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TRANSMITTAL LETTER (General - Patent Pending)			Docket No. CRI-3US	
In Re Application Of: I	Donald Mickle et al.			
Serial No. 09/363,100	Filing Date July 29, 1999	Examiner Afremova, Vera	Group Art Unit 1651	
Title: MESENCHYMA	L STEM CELL TRANSPLANTA	TION INTO DAMAGED MY	OCARDIUM	
Patent Appeals and In	onse to Office Action; Combined N terferences & Petition for Extension erest (Revocation of Prior Powers)	Notice of Appeal from the Prin on of Time under 37 CFR 1.13	nary Examiner to the Board of 6(a); Power of Attorney by	
as described belo ⊠ Charge t ⊠ Credit ar	is required.	and credit Deposit Account I	No. <b>07-1074</b>	
Madge R. Kanter Reg. No. 35,211 GENZYME CORPORA One Kendall Square Cambridge, MA 02139 Tel. (617) 761-8485 Fax (617) 252-7977	Signature	on first class mail ur Commissioner of D.C. 20231.	s document and fee is being deposited with the U.S. Postal Service as ider 37 C.F.R. 1.8 and is addressed to the Patents and Trademarks, Washington, of Person Mailing Correspondence	
ω.		Typed or Printer	Name of Person Mailing Correspondence	

Docket Number CRI-3US

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

: Donald Mickle et al.

Serial Number

09/363,100

Confirmation Number

7723

Examiner

Afremova, Vera

Art Unit

1651

Filed

: July 29, 1999

For

MESENCHYMAL STEM CELL

TRANSPLANTATION INTO DAMAGED

MYOCARDIUM

Commissioner of Patents and Trademarks United States Patent and Trademark Office Washington, D.C. 20231

## STATEMENT UNDER 37 C.F.R. § 3.73(b)

Sir:

This Statement Under 37 C.F.R. § 3.73(b) accompanies a POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST, filed in the above-identified application concurrently berewith.

Evidence establishing that Genzyme Corporation is the assignee of the entire right, title and interest in the above-identified application, may be found in the Assignment recorded on December 16, 1999 at Reel 10462 and Frame 0885.

Evidence that the undersigned is authorized to act on behalf of Genzyme may be found in the attached SIGNATURE AUTHORITY.

Respectfully submitted,

Madge R. Kanter (Reg. No. 35,211)

Attorney for Applicant Genzyme Corporation One Kendall Square

Cambridge, Massachusetts 02139

Dated: December 26, 2002 Tel. (617) 761-8485



GENZYME CORPORATION
ONE KENDALL SQUARE
CAMBRIDGE, MA 02139-1562. U.S.A.
617-252-7500
FAX 617-252-7600

### SIGNATURE AUTHORITY

I, Thomas J. DesRosier, Senior Vice President and General Counsel of Genzyme Corporation hereby appoint Madge R. Kanter, Richard Allison, Elizabeth Lassen and Bart G. Newland, all Managing Intellectual Property Counsel of Genzyme Corporation, with full power and authority to transact any and all business before the United States Patent and Trademark Office, and any foreign counterpart patent office, with the powers of a Corporate Officer of Genzyme Corporation.

Date: September 24, 2001

Thomas J. DesRosier, Esquire

Senior Vice President and General Counsel

GENZYME CORPORATION

# **G** hzyme Corporation

One Kendall Square, 1400 Building, 4th Floor Cambridge, Massachusetts 02139 U.S.A.

Telephone: (617) 252-7500 Facsimile: (617) 252-7977

Maggie Kanter Direct Dial: (617) 761-8485 maggie.kanter @genzyme.com

# LEGAL DEPARTMENT

FAX RECEIVED

UEU 27 2002

GROUP 1600

# **Facsimile**

To:	Vera Afremova	From:	Maggie Kanter	OFFICIA
Fax:	(703) 308-4242	Pagesi	22	O/H
Phone:	(703) 308-9351	Date:	12/26/2002	
Re:	CRI-3US	CC:		
	Application No.: 09/363,100			
	Title: MESENCHYMAL STEM CELI	L		
	TRANSPLANTATION INTO			
	DAMAGED MYOCARDIUM			

# NOTICE OF CONFIDENTIALITY

This transmission is intended only for the addressee(s) listed above, and may contain information that is confidential or privileged. If you are not the intended recipient or an agent responsible for delivering it to the intended recipient, y u are h reby n tified y u have received this document in error an any use, disclosure, copying or communication of the contents f this transmission is prohibit d. If this message was received in error, pleas tel phone us immediately.